Joshua Schafer

Josh Schafer has a diverse work experience spanning over several years. Josh is currently the Chief Commercial Officer and EVP Business Development at Zevra Therapeutics since January 2023. Prior to this, they served as a Board Member at PHARNEXT from July 2020. Josh also held the position of Chief Executive Officer (interim) and Chair of the Board at PHARNEXT from October 2022 to February 2023. In 2017, Schafer became a Board Member at Shuttle Pharmaceuticals, a publically traded clinical-stage pharmaceutical company. Before joining Zevra Therapeutics and PHARNEXT, they worked at Mallinckrodt Pharmaceuticals, where they served as the Senior Vice President and General Manager for the Autoimmune & Rare Disease Business from February 2021 to December 2022. Josh also held roles as the Senior Vice President and Chief Strategy Officer from July 2019 to February 2021 and General Manager, International and Vice President, Business Development & Licensing from May 2015 to July 2019. Prior to Mallinckrodt Pharmaceuticals, they served as the Vice President, Global Therapeutic Area Head, Oncology & Rare Diseases at Astellas Pharma from May 2009 to May 2015. Schafer's career also includes positions at Takeda, Cognia, Pfizer (formerly Searle), and Accenture. Overall, their work experience spans across various healthcare industries and includes roles in leadership, business development, marketing, and consultancy.

Josh Schafer has an MBA degree in Marketing and Finance from Northwestern University - Kellogg School of Management. Josh also holds an MSc degree in Biotechnology from Northwestern University. Furthermore, they have a BS degree in Biology and German from the University of Notre Dame. Additionally, Josh is currently working towards a Level 4 Diploma from the Wine & Spirit Education Trust, having already achieved Level 3.